Monte Rosa Therapeutics Ownership | Who Owns Monte Rosa Therapeutics?
Monte Rosa Therapeutics Ownership Summary
Monte Rosa Therapeutics is owned by 15.16% institutional investors, 0.81% insiders, and 84.03% retail investors. Nea management company is the largest institutional shareholder, holding 9.36% of GLUE shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.83% of its assets in Monte Rosa Therapeutics shares.
GLUE Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Monte Rosa Therapeutics | 15.16% | 0.81% | 84.03% |
| Sector | Healthcare Stocks | 232.20% | 10.74% | -142.94% |
| Industry | Biotech Stocks | 382.11% | 10.55% | -292.66% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Nea management company | 7.69M | 9.36% | $57.00M |
| Bvf inc/il | 5.66M | 6.89% | $41.94M |
| Baker bros. advisors lp | 4.92M | 5.98% | $36.43M |
| Price t rowe associates inc /md/ | 4.64M | 5.64% | $34.36M |
| Versant venture management | 4.38M | 5.32% | $68.72M |
| Blackrock funding, inc. /de | 4.18M | 5.07% | $65.56M |
| Suvretta capital management | 3.36M | 4.09% | $24.90M |
| Vanguard group | 3.25M | 3.94% | $50.91M |
| Blackrock | 2.36M | 3.92% | $8.83M |
| Fmr | 2.81M | 3.42% | $20.84M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Versant venture management | 4.38M | 45.49% | $68.72M |
| Aisling capital management lp | 1.47M | 4.82% | $23.09M |
| Nea management company | 7.69M | 3.13% | $57.00M |
| Silverarc capital management | 1.03M | 2.24% | $16.14M |
| Bvf inc/il | 5.66M | 1.70% | $41.94M |
| Rangeley capital | 113.00K | 0.72% | $837.33K |
| Suvretta capital management | 3.36M | 0.64% | $24.90M |
| Parkwood | 708.00K | 0.48% | $5.25M |
| Alphabet | 1.46M | 0.45% | $10.85M |
| Vestal point capital, lp | 800.00K | 0.27% | $5.93M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Vestal point capital, lp | 800.00K | 0.27% | 800.00K |
| Fmr | 2.81M | 0.00% | 524.22K |
| Marshall wace, llp | 902.83K | 0.01% | 456.75K |
| Norges bank | 445.87K | 0.00% | 445.87K |
| Blackrock funding, inc. /de | 4.18M | 0.00% | 366.03K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Avoro capital advisors | - | - | -3.73M |
| Price t rowe associates inc /md/ | 4.64M | 0.00% | -1.69M |
| Versant venture management | 4.38M | 45.49% | -1.27M |
| Renaissance | - | - | -395.73K |
| Readystate asset management lp | - | - | -287.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vestal point capital, lp | 800.00K | 0.27% | 800.00K | $5.93M |
| Norges bank | 445.87K | 0.00% | 445.87K | $3.09M |
| Adar1 capital management | 215.75K | 0.15% | 215.75K | $1.60M |
| Rangeley capital | 113.00K | 0.72% | 113.00K | $837.33K |
| Point72 asset management | 90.42K | 0.00% | 90.42K | $670.00K |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -6.00 |
| Us bancorp \de\ | -26.00 |
| Capital performance advisors llp | -29.00 |
| Skopos labs | -92.00 |
| Parkside financial bank & trust | -95.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 65 | -51.13% | 12,491,437 | -79.19% | 15 | 0.28% | 46 | -24.59% | 9 | -77.50% |
| Sep 30, 2025 | 47 | -59.83% | 19,971,709 | -67.89% | 24 | 0.42% | 21 | -72.37% | 16 | -11.11% |
| Jun 30, 2025 | 116 | 7.41% | 62,164,335 | 4.44% | 75 | 1.44% | 75 | 70.45% | 18 | -60.87% |
| Mar 31, 2025 | 6 | -94.44% | 15,774,831 | -74.13% | 19 | 0.35% | 3 | -95.77% | 1 | -94.12% |
| Dec 31, 2024 | 55 | -34.52% | 25,603,232 | -48.56% | 31 | 0.85% | 40 | -25.93% | 4 | -66.67% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.16M | 2.83% | 315.85K |
| Avantis US Small Cap Value ETF | 2.09M | 2.74% | 15.42K |
| T. Rowe Price New Horizons | 1.71M | 2.24% | - |
| US Small-Cap Growth II Equity Comp | 1.71M | 2.24% | -1.01K |
| FIAM Small Cap Core Composite | 1.58M | 2.08% | 323.67K |
| HBM Healthcare Investments AG Ord | 1.41M | 1.85% | - |
| Fidelity Growth Compy Commingled Pl O | 970.82K | 1.58% | - |
| T. Rowe Price Health Sciences | 1.19M | 1.56% | -93.10K |
| State Street® SPDR® S&P® Biotech ETF | 1.16M | 1.52% | -6.23K |
| iShares Russell 2000 ETF | 1.13M | 1.48% | 530.48K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 02, 2026 | Dunn Edmund | Principal Accounting Officer | Sell | $9.38K |
| Feb 27, 2026 | Dunn Edmund | Principal Accounting Officer | Sell | $455.51K |
| Feb 23, 2026 | Janku Filip | Chief Medical Officer | Sell | $179.16K |
| Jan 07, 2026 | Warmuth Markus | President & CEO | Sell | $7.59K |
| Jan 07, 2026 | Warmuth Markus | President & CEO | Sell | $86.16K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 12 |
| 2025 Q2 | - | 1 |
| 2025 Q1 | 1 | - |
| 2024 Q4 | - | 3 |
| 2024 Q3 | - | 5 |
GLUE Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools